A network pharmacology-based approach to explore the active ingredients and molecular mechanism of Shen-Kui-Tong-Mai granules on a rat model with chronic heart failure
| Autor: | Hong Huang, Junyao Xu, Siqi Zhang, Jing Zhao, Shun Liu, Lei Tian, Haidan Wang, Zhirong Geng, Shihai Yan |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of Pharmacy and Pharmacology. |
| ISSN: | 2042-7158 0022-3573 |
| DOI: | 10.1093/jpp/rgad009 |
| Popis: | ObjectivesThis study aimed to comprehensively investigate the potential active components and therapeutic mechanisms of Shen-Kui-Tong-Mai granule (SKTMG) in the treatment of heart failure.MethodsNetwork pharmacology combined with ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UHPLC–MS/MS), molecular docking, and in vivo validation was performed to identify the active components and the potential targets for SKTMG to improve chronic heart failure (CHF).Key findingsThe network pharmacology identified 192 active compounds and 307 potential consensus targets for SKTMG. On the other hand, network analysis discovered 10 core target genes related to the MAPK signal pathway. These genes include AKT1, STAT3, MAPK1, P53, SRC, JUN, TNF, APP, MAPK8 and IL6. The molecular docking results revealed that the SKTMG components were luteolin, quercetin, astragaloside IV and kaempferol, which could bind AKT1, MAPK1, P53, JUN, TNF and MAPK8. Additionally, SKTMG inhibited phosphorylation of AKT, P38, P53 and c-JUN, and reduced TNF-α expression in CHF rats.ConclusionsThe present results demonstrated that network pharmacology combined with UHPLC–MS/MS, molecular docking and in vivo validation can facilitate the identification of active components and the potential targets for SKTMG to improve CHF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|